4.5 Article

An adaptive randomized clinical trial in interstitial cystitis/bladder pain syndrome evaluating efficacy of ASP3652 and the relationship between disease characteristics and Hunner's lesions

Journal

WORLD JOURNAL OF UROLOGY
Volume 39, Issue 6, Pages 2065-2071

Publisher

SPRINGER
DOI: 10.1007/s00345-020-03372-z

Keywords

Interstitial cystitis; Phenotype; Fatty acid amide hydrolase (FAAH) inhibitor; Endocannabinoids; Hunner's lesion; Patient characteristics

Funding

  1. Astellas Pharma Europe BV

Ask authors/readers for more resources

This study evaluated the efficacy and safety of the fatty acid amide hydrolase (FAAH) inhibitor ASP3652 in patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and phenotyped patients based on Hunner's lesions (HL). ASP3652 was found to be safe and well tolerated in treatment, but did not demonstrate significant efficacy in IC/BPS. Differences observed between HL+ and HL- patients suggest that diagnosis and treatment of IC/BPS may need to be approached differently for these two phenotypes.
Purpose The primary purpose of this study was to evaluate the effect of the fatty acid amide hydrolase (FAAH) inhibitor ASP3652 on efficacy and safety in patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). The secondary purpose was to evaluate phenotyping based on Hunner's lesions (HL). Methods In this randomized trial, adult female patients with moderate/severe IC/BPS received 12 weeks of treatment with an oral dose of ASP3652 (50, 150, or 300 mg twice daily) or placebo. A Bayesian model was employed using accumulating data to adjust the randomization probability and to analyze the primary efficacy variable (change from baseline to end of treatment in Mean Daily Pain [MDP; range 0-10]). Study outcomes and patient characteristics of patients with and without HL (HL+ and HL-) were compared. Results In total, 287 patients were randomized. The 300 mg dose group (n = 97) showed the largest effect, i.e., a mean change from baseline to end of treatment of -1.73 in MDP. However, the mean difference from placebo was 0.02. The probability that this dose was better than placebo was 13.5%. Adverse event incidence was low and similar between study groups. HL+ patients were older and had more severe symptoms than HL-. An association was suggested in HL+ patients between changes in micturition frequency and MDP (R = 0.41 [95% CI 0.18, 0.63]), which was not observed in HL- (R = 0.04 [95% CI -0.16, 0.29]). Conclusion ASP3652 was safe and well tolerated, but did not show efficacy in IC/BPS. The observed differences between HL+ and HL- suggest that IC/BPS diagnosis and treatment may be approached differently in these two phenotypes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available